Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular diseaseLilly's established capabilities ...

The global Biosimilars Market, valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to advance at a resilient ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...

Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company ...

Biotech firms focused on gene therapies traded higher after Eli Lilly (NYSE:LLY) agreed to acquire Boston-based gene-editing ...

Boston-based Verve Therapeutics is a Nasdaq-traded company focused on genetic medicines for cardiovascular disease.

Eli Lilly said Tuesday that it will acquire Verve Therapeutics, a biotech developing gene-editing therapies for cardiovascular disease.

Eli Lilly is placing a bold $1.3 billion bet on Verve Therapeutics’ experimental gene-editing treatment for heart disease.

Boston-based Verve is a rare example of a gene editing company targeting a disease that affects a large population, offering ...

Lilly confirmed it would buy a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.

Biotech stock Verve Therapeutics Inc (NASDAQ:VERV) is up 75.3% to trade at $10.99 at last check amid news that peer Eli Lilly ...